DrugPatentWatch Database Preview

Lesinurad - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lesinurad and what is the scope of freedom to operate?

Lesinurad is the generic ingredient in one branded drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lesinurad has one hundred and ninety-three patent family members in forty countries.

One supplier is listed for this compound.

Summary for lesinurad

International Patents:	193
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	61
Clinical Trials:	19
Patent Applications:	95
DailyMed Link:	lesinurad at DailyMed

Recent Clinical Trials for lesinurad

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medpace, Inc.	Phase 4
Ironwood Pharmaceuticals, Inc.	Phase 4
Ardea Biosciences, Inc.	Phase 1

See all lesinurad clinical trials

Pharmacology for lesinurad

Drug Class	Urate Transporter 1 Inhibitor
Mechanism of Action	Urate Transporter 1 Inhibitors Cytochrome P450 3A Inducers

Synonyms for lesinurad

(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid

09ERP08I3W

2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid

2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-acetic acid

2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid

2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid

2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid

3777AH

878672-00-5

AC-29310

Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-

Acetic acid,[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-

ACN-050764

AK323774

AKOS027327368

BCP06435

BDBM37953

C17H14BrN3O2S

CHEBI:90929

CHEMBL2105720

CS-1389

D09921

DB11560

EX-A1289

FGQFOYHRJSUHMR-UHFFFAOYSA-N

GTPL7673

HY-15258

KB-78121

KS-00000LAE

Lesinurad (RDEA-594)

Lesinurad (RDEA594 pound(c)

Lesinurad (RDEA594)

Lesinurad (USAN/INN)

Lesinurad [USAN:INN]

Lesinurad, >=98% (HPLC)

MolPort-039-138-666

RDEA 594

RDEA-594

RDEA594

s4640

SB16705

SC-94287

SCHEMBL842962

UNII-09ERP08I3W

US10093631, Compound Lesinurad

W-5949

ZINC84757007

Zurampic

Zurampic (TN)

US Patents and Regulatory Information for lesinurad

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No

International Patents for lesinurad

Country	Patent Number	Estimated Expiration
Singapore	155246
Taiwan	I415840
Japan	2011504935

Supplementary Protection Certificates for lesinurad

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2217577	2016016	Norway		PRODUCT NAME: LESINURAD, ELLER ET; REG. NO/DATE: EU/1/15/1080 20160303
2135608	93169	Luxembourg		PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
2217577	122019000008	Germany		PRODUCT NAME: DUZALLO - ALLOPURINOL / LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/18/1300 20180823